Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LISA PO-LAN JONES

Allopathic & Osteopathic Physicians Radiology Diagnostic Radiology

NPI
1841227683
CMS profile
529508
Location
PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$430,142.50

192 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $430,142.50 192

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme Corporation $430,142.50 192

Page 3 of 4; records 101–150 of 192 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LISA PO-LAN JONES

NPI 1841227683 · CMS profile ID 529508

Allopathic & Osteopathic Physicians / Radiology / Diagnostic Radiology

PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 192 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1841227683?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LISA PO-LAN JONES, NPI 1841227683, CMS profile ID 529508. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 192 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1841227683?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). LISA PO-LAN JONES, NPI 1841227683, CMS profile ID 529508. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 192 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1841227683?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
LISA PO-LAN JONES, NPI 1841227683, CMS profile ID 529508, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 192 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1841227683?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

192 matching records · $430,142.50 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 192 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 192.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme Corporation $5,400.0006/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848515587 CMS
Merck Sharp & Dohme Corporation $4,500.0006/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848551945 CMS
Merck Sharp & Dohme Corporation $300.0006/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848552079 CMS
Merck Sharp & Dohme Corporation $180.0006/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848599637 CMS
Merck Sharp & Dohme Corporation $2,340.0006/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848599639 CMS
Merck Sharp & Dohme Corporation $4,980.0006/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848641197 CMS
Merck Sharp & Dohme Corporation $6,000.0006/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848719467 CMS
Merck Sharp & Dohme Corporation $480.0006/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848736013 CMS
Merck Sharp & Dohme Corporation $6,020.0006/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848736149 CMS
Merck Sharp & Dohme Corporation $840.0005/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848422967 CMS
Merck Sharp & Dohme Corporation $3,600.0005/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848422975 CMS
Merck Sharp & Dohme Corporation $3,060.0005/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848423117 CMS
Merck Sharp & Dohme Corporation $360.0005/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848472943 CMS
Merck Sharp & Dohme Corporation $60.0005/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848533109 CMS
Merck Sharp & Dohme Corporation $120.0005/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848533111 CMS
Merck Sharp & Dohme Corporation $60.0005/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848551949 CMS
Merck Sharp & Dohme Corporation $1,440.0005/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848599525 CMS
Merck Sharp & Dohme Corporation $3,780.0005/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848599643 CMS
Merck Sharp & Dohme Corporation $4,635.0005/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848611225 CMS
Merck Sharp & Dohme Corporation $540.0005/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848611227 CMS
Merck Sharp & Dohme Corporation $4,860.0005/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848621071 CMS
Merck Sharp & Dohme Corporation $1,680.0005/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848621209 CMS
Merck Sharp & Dohme Corporation $6,300.0005/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848663039 CMS
Merck Sharp & Dohme Corporation $80.0005/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848682595 CMS
Merck Sharp & Dohme Corporation $2,880.0004/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848423115 CMS
Merck Sharp & Dohme Corporation $395.0004/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848423119 CMS
Merck Sharp & Dohme Corporation $540.0004/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848463009 CMS
Merck Sharp & Dohme Corporation $360.0004/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848515585 CMS
Merck Sharp & Dohme Corporation $4,920.0004/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848569585 CMS
Merck Sharp & Dohme Corporation $542.5004/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848593301 CMS
Merck Sharp & Dohme Corporation $2,520.0004/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848599641 CMS
Merck Sharp & Dohme Corporation $60.0004/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848621073 CMS
Merck Sharp & Dohme Corporation $600.0004/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848641069 CMS
Merck Sharp & Dohme Corporation $840.0004/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848641201 CMS
Merck Sharp & Dohme Corporation $8,640.0004/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848641203 CMS
Merck Sharp & Dohme Corporation $6,300.0004/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848700535 CMS
Merck Sharp & Dohme Corporation $4,500.0004/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848704937 CMS
Merck Sharp & Dohme Corporation $1,200.0004/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848704939 CMS
Merck Sharp & Dohme Corporation $360.0004/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848704941 CMS
Merck Sharp & Dohme Corporation $2,415.0004/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848736015 CMS
Merck Sharp & Dohme Corporation $3,720.0004/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848736289 CMS
Merck Sharp & Dohme Corporation $2,700.0003/10/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848422973 CMS
Merck Sharp & Dohme Corporation $5,040.0003/10/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848423621 CMS
Merck Sharp & Dohme Corporation $60.0003/10/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848423623 CMS
Merck Sharp & Dohme Corporation $1,560.0003/10/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848449581 CMS
Merck Sharp & Dohme Corporation $2,280.0003/10/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848449583 CMS
Merck Sharp & Dohme Corporation $540.0003/10/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848472805 CMS
Merck Sharp & Dohme Corporation $480.0003/10/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848532989 CMS
Merck Sharp & Dohme Corporation $80.0003/10/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848593563 CMS
Merck Sharp & Dohme Corporation $3,500.0003/10/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848611351 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $101,250.00 105
PY2020 $363,490.00 191
PY2021 $430,142.50 192
PY2024 $86.15 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $19,985.00 11
PY2024 Recipient $15,380.00 4
PY2023 Recipient $71,050.00 12
PY2022 Recipient $44,985.00 11
PY2021 Recipient $42,860.00 11
PY2020 Recipient $74,880.00 4
PY2019 Recipient $60,540.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

11 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient E.R. Squibb & Sons, L.L.C. $75.00 10/03/2025 Covered Recipient Physician A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physicians Choice in Patients with Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC who are Ineligible for Anti-PD1/PD-L1 Treatment No dispute reported 06/30/2026 1236002239
Recipient E.R. Squibb & Sons, L.L.C. $840.00 08/08/2025 Covered Recipient Physician A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of BMS-986369 in Participants with Relapsed or Refractory T-cell Lymphomas in Japan No dispute reported 06/30/2026 1236002227
Recipient E.R. Squibb & Sons, L.L.C. $780.00 07/03/2025 Covered Recipient Physician A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge No dispute reported 06/30/2026 1236002237
Recipient E.R. Squibb & Sons, L.L.C. $690.00 04/03/2025 Covered Recipient Physician A Phase 3 Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or an Investigators Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer No dispute reported 06/30/2026 1236002229
Recipient E.R. Squibb & Sons, L.L.C. $960.00 04/03/2025 Covered Recipient Physician A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer No dispute reported 06/30/2026 1236002233
Recipient E.R. Squibb & Sons, L.L.C. $2,220.00 04/03/2025 Covered Recipient Physician A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS 986205 in Participants with Muscle-Invasive Bladder Cancer No dispute reported 06/30/2026 1236002235
Recipient Regeneron Pharmaceuticals, Inc. $595.00 03/04/2025 Covered Recipient Physician A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184118923
Recipient Regeneron Pharmaceuticals, Inc. $1,105.00 03/04/2025 Covered Recipient Physician A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184118925
Recipient Regeneron Pharmaceuticals, Inc. $765.00 03/04/2025 Covered Recipient Physician A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184118927
Recipient E.R. Squibb & Sons, L.L.C. $9,000.00 01/03/2025 Covered Recipient Physician A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations in Recurrent and Metastatic Microsatellite Instability High (MSI-H) and Non-MSI-H Colon Cancer No dispute reported 06/30/2026 1236002231
Recipient Eli Lilly and Company $2,955.00 01/03/2025 Covered Recipient Physician A STUDY OF SELPERCATINIB (LY3527723) IN PARTICIPANTS WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (LIBRETTO-431) No dispute reported 06/30/2026 1187873495